Chimeric Glycoprotein Nanoparticles Elicit Robust Neutralizing Antibodies Against Epstein–Barr Virus
Identification
- Public canonical key
- radar:r-45b29a3b8d75eafa7ee0ef5d5f349c7b
- Authors
- Cong Sun · Chu Xie · Xin‐Yan Fang · Dong‐Chun Hong · Haoyu Zhang · Ping Wu · Yina Liu · Guo‐Long Bu · De‐Hai Cao · Minyi Situ · Yong‐Jian Peng · Jing Wang · Guo‐Kai Feng · Qian Zhong · Zheng Liu · Mu‐Sheng Zeng
- Reported year
- 2025
- Reported language
- en
- Source type
- article
- First detected
- 2026-11-14T02:04:20.559729+00:00
- Last metadata observation
- 2026-11-14T02:04:20.559729+00:00
- Last HTTP verification
- Not checked
Institutions reported by the source
Sun Yat-sen University Cancer Center · State Key Laboratory of Oncology in South China · Southern University of Science and Technology
Reported affiliation countries
CN
Documentary abstract — original language
Epstein‒Barr virus (EBV) is a ubiquitous gammaherpesvirus linked to a broad spectrum of malignancies and autoimmune diseases with no approved therapeutic drugs or vaccines. EBV infection relies on the viral glycoproteins gB and gHgL, which, together, function as the fusion apparatus, mediating viral recognition and membrane fusion in both epithelial and B cells. Despite discovering potent neutralizing antibodies targeting gB and gHgL, the heterogeneous antigen structures and distribution of multiple glycoproteins in the virion hinder rational vaccine design targeting this apparatus complex. In this study, Chimeric nanoparticles (Chimeric-NPs) are designed that co-display EBV fusion apparatus and induce significantly more neutralizing antibodies in mice and nonhuman primates than the cocktail counterparts. It is further demonstrated that the Chimeric-NPs elicited neutralizing antibodies predominantly targeting gB, closely mimicking the antibody induction pattern by the whole EBV virion. Additionally, single-BCR sequencing is used to analyze the B cell response to Chimeric-NP, and a novel gB neutralizing antibody Fab5 targeting a new vulnerable site EBV gB is identified. These findings provide novel candidates and vaccine design strategies for EBV and reveal the underlying mechanisms of antibody induction and immune response regulation by chimera vaccines, with potential implications for all multi-antigen-harbored pathogens.
Identifiers
- OPENALEX
- https://openalex.org/W4414812902
- DOI
- 10.1002/adma.202507012
- PMID
- https://pubmed.ncbi.nlm.nih.gov/41045177
Documentary context
- Documentary family
- article
- Source-reported types
- article
- Publishers
- Wiley
Entity mentions are not evidence of legal recognition. Jurisdiction studied is separate from author affiliation country.
Sources
OpenAlex · Record 1
Cite this reference
Cong Sun; Chu Xie; Xin‐Yan Fang; Dong‐Chun Hong; Haoyu Zhang; Ping Wu; Yina Liu; Guo‐Long Bu; De‐Hai Cao; Minyi Situ; Yong‐Jian Peng; Jing Wang; Guo‐Kai Feng; Qian Zhong; Zheng Liu; Mu‐Sheng Zeng. Chimeric Glycoprotein Nanoparticles Elicit Robust Neutralizing Antibodies Against Epstein–Barr Virus. 2025. https://doi.org/10.1002/adma.202507012
JSON · CSL-JSON · BibTeX · RIS · CSV · JSON-LD ·
APA, Chicago, ISO 690: bibliographic formats using available fields. OSCOLA / Bluebook: structured data only; full legal citation compliance is not claimed without verification of required elements.
- APA
- Cong Sun; Chu Xie; Xin‐Yan Fang; Dong‐Chun Hong; Haoyu Zhang; Ping Wu; Yina Liu; Guo‐Long Bu; De‐Hai Cao; Minyi Situ; Yong‐Jian Peng; Jing Wang; Guo‐Kai Feng; Qian Zhong; Zheng Liu; Mu‐Sheng Zeng. (2025). Chimeric Glycoprotein Nanoparticles Elicit Robust Neutralizing Antibodies Against Epstein–Barr Virus. https://doi.org/10.1002/adma.202507012
- Chicago
- Cong Sun; Chu Xie; Xin‐Yan Fang; Dong‐Chun Hong; Haoyu Zhang; Ping Wu; Yina Liu; Guo‐Long Bu; De‐Hai Cao; Minyi Situ; Yong‐Jian Peng; Jing Wang; Guo‐Kai Feng; Qian Zhong; Zheng Liu; Mu‐Sheng Zeng. Chimeric Glycoprotein Nanoparticles Elicit Robust Neutralizing Antibodies Against Epstein–Barr Virus. 2025. https://doi.org/10.1002/adma.202507012
- ISO 690
- Cong Sun; Chu Xie; Xin‐Yan Fang; Dong‐Chun Hong; Haoyu Zhang; Ping Wu; Yina Liu; Guo‐Long Bu; De‐Hai Cao; Minyi Situ; Yong‐Jian Peng; Jing Wang; Guo‐Kai Feng; Qian Zhong; Zheng Liu; Mu‐Sheng Zeng. Chimeric Glycoprotein Nanoparticles Elicit Robust Neutralizing Antibodies Against Epstein–Barr Virus. 2025. https://doi.org/10.1002/adma.202507012
Warning: Undefined array key "last_link_verified" in /home/clients/e27d81e12f04d2bfd747aa264540ac56/sites/_UDTR_APP/legal_library_reference.php on line 31
UDTR Global Rights of Nature Legal Library. Chimeric Glycoprotein Nanoparticles Elicit Robust Neutralizing Antibodies Against Epstein–Barr Virus. Documentary record: https://www.declarationuniverselledesdroitsdelarbre.org/global-rights-of-nature-radar/reference/r-45b29a3b8d75eafa7ee0ef5d5f349c7b/ · Last HTTP verification: not performed
Research dossiers and documentary relations
Source roles
Bibliographic / original publication source · https://doi.org/10.1002/adma.202507012
An authority link alone does not verify a legal claim. Abstracts and full texts remain subject to their source terms.
Documentary status
Relevance pending
Library
This identity is not yet included in the Legal Library.